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 Context.—Pseudocarcinomatous urothelial hyperplasia
(PCUH) architecturally and cytologically mimics cancer.
The urine cytology features of PCUH have not been
described.
Objective.—To describe PCUH features in urine cytology.
Design.—We reviewed urine cytology cases with concurrent PCUH tissue specimens from 5 academic institutions and classified them by using The Paris System criteria.
Results.—Thirty-nine patients included 31 men and 8
women with a mean age of 67 years (range, 39–87 years).
All patients had prior pelvic irradiation, and most
presented with hematuria (n ¼ 27). The specimens included
voided urine (n ¼ 16); bladder washing (n ¼ 11); and urine,
not otherwise specified (n ¼ 12). The specimen preparation
included cytospin (n ¼ 29) and ThinPrep (n ¼ 10). Original
interpretations were negative for high-grade urothelial
carcinoma (n ¼ 28), atypical urothelial cells (AUCs; n ¼
10), and high-grade urothelial carcinoma (HGUC; n ¼ 1).
Twenty-five urine specimens (64%) had findings of PCUH.
These specimens were moderately cellular and composed
of sheets, cohesive groups, or isolated urothelial cells.

Nucleoli were present in 23 cases. The nuclear membrane
was smooth to irregular (n ¼ 9), smooth (n ¼ 8), and
irregular (n ¼ 8). The chromatin was glassy (n ¼ 8),
vesicular (n ¼ 7), hyperchromatic (n ¼ 7), and vesicular to
finely granular (n ¼ 3). The cytoplasm varied from dense
squamoid, to finely vacuolated, to vacuolated. Nucleomegaly was observed in all 25 specimens, and nuclearcytoplasmic ratio greater than 0.5 was seen in 11 of 25
cases (44%). The background contained acute inflammation (n ¼ 14), was clean (n ¼ 9), and contained red blood
cells (n ¼ 2). All cases originally interpreted as AUCs and
HGUC had PCUH features.
Conclusions.—PCUH urine features can overlap with
AUCs, HGUC, and other nonurothelial malignancies. In
our cohort, 44% (11 of 25) of urine specimens with PCUH
changes were initially misclassified. Recognition of cytologic features of PCUH is important to avoid overcalling
reactive changes.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2022-0125OA)
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seudocarcinomatous urothelial hyperplasia (PCUH) was
first described by Baker and Young in 2000.1 In 4 cases
following radiation therapy, the authors described an
inverted proliferation of urothelial nests within the lamina
propria, which can mimic invasive urothelial carcinoma.
Chan and Epstein2 subsequently expanded its morphologic
diagnostic criteria. While in earlier reports radiation was
considered a sole causative factor, Lane and Epstein3 more
recently described similar histologic changes with other
predisposing conditions (eg, severe peripheral vascular
disease, chronic bladder irritation, chemotherapy), which
are believed to compromise the blood supply to the bladder
mucosa. Finally, in the largest series to date by Kryvenko
and Epstein,4 it was shown that PCUH is not associated
with an increased subsequent risk of bladder carcinoma and
is truly a reactive condition. Although the histologic features
of PCUH are well described, the cytomorphologic features
of PCUH in urine cytology specimens have not been
previously described. Herein, we assemble a large multiinstitutional cohort to analyze the cytologic findings of
PCUH in urine specimens and assess the potential
diagnostic challenges.
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MATERIALS AND METHODS
A retrospective search of the pathology archives at the University
of Miami (Miami, Florida), University of Florida College of
Medicine (Gainesville), University of Alabama at Birmingham
(Birmingham), Henry Ford Health System (Detroit, Michigan), and
University of Southern California Keck School of Medicine (Los
Angeles) was performed that identified 34 cases of bladder tissue
specimens showing PCUH with concurrent urine cytology.
Additional 5 cases were contributed from the consultation files of
the senior author. We defined PCUH as nests of urothelium
extending into the lamina propria in a background of extensive
vasodilation, vascular congestion, fresh and remote blood extravasation, chronic inflammation in the lamina propria, and intravascular fibrin clots and stromal fibrin deposition (Figure 1, A through
C).1–3,5 Mild to moderate cytologic atypia and mitotic activity (with
the exception of atypical forms) were allowable within the
spectrum of tissue findings in PCUH (Figure 1, D).
All cytology cases were retrieved by the contributing institutions
and centrally re-reviewed by a board-certified cytopathologist (lead
author) and reclassified with The Paris System for Reporting
Urinary Cytology (TPS) criteria.6 The nature of the specimen
collection (eg, voided urine or bladder wash) and the methods of
preparation (cytospin or ThinPrep) were recorded. The following
cytologic features were assessed: (1) presence of nucleoli, (2)
nuclear membrane irregularity, (3) chromatin quality (vesicular to
finely granular, coarse, hyperchromatic, or glassy), (4) cytoplasm,
(5) nuclear-cytoplasmic (N:C) ratio (.0.5 or .0.7), and (6)
background findings (inflammation, red blood cells, and necrosis).
The clinical data were obtained from patient medical records.

criteria, 9 cases remained as NHGUC, 3 cases remained as
AUCs, 7 cases changed from AUCs to NHGUC, 5 cases
changed from NHGUC to AUCs, and 1 case changed from
HGUC to AUCs. The background contained acute inflammation (n ¼ 14), was clean (n ¼ 9), and contained red blood
cells (n ¼ 2). The background findings were similar in
cytospin or ThinPrep preparations. In all cases originally
interpreted as AUCs and HGUC, after re-review we
believed that the cytologic findings were related to PCUH.

RESULTS
We identified 39 cases that included 31 men and 8 women
with a mean age of 67 years (range, 39–87 years). Patients
with available clinical information presented with hematuria
(n ¼ 27), dysuria (n ¼ 1), incontinence (n ¼ 1), recurrent
urinary tract infections (n ¼ 1), and hydronephrosis (n ¼ 1).
All 39 patients had undergone prior pelvic irradiation for
prostate cancer (n ¼ 29), cervical cancer (n ¼ 5), urothelial
cancer (n ¼ 3), endometrial cancer (n ¼ 1), or colon cancer (n
¼ 1). The median time from radiation to the diagnosis of
PCUH was 43 months (range, 6–115 months). The specimen
types included voided urine (n ¼ 16), bladder washing (n ¼
11), and urine not otherwise specified (n ¼ 12). The
specimen preparations included cytospin (n ¼ 29) and
ThinPrep (n ¼ 10). The urine cytology specimens were
originally interpreted as negative for high-grade urothelial
carcinoma (NHGUC; n ¼ 28), atypical urothelial cells
(AUCs; n ¼ 10), and high-grade urothelial carcinoma
(HGUC; n ¼ 1). The patient with the HGUC diagnosis did
not have a record of urothelial carcinoma, and no such
diagnosis was rendered during the subsequent 4 years of
follow-up.
Of 39 cases, 25 urine specimens had findings that could be
attributed to PCUH (Table). These specimens were moderately cellular and composed of sheets (Figure 1, E), clusters
(Figure 1, F), or isolated urothelial cells. Twenty-three cases
demonstrated prominent nucleoli. The nuclear membrane
was smooth to irregular (n ¼ 9), smooth (n ¼ 8), and
irregular (n ¼ 8). The chromatin was glassy (n ¼ 8) (Figure 2,
A), vesicular (n ¼ 7) (Figure 2, B), hyperchromatic (n ¼ 7)
(Figure 2, C), and vesicular to finely granular (n ¼ 3) (Figure
2, D). The cytoplasm varied from dense squamoid to finely
vacuolated to vacuolated (Figure 2, E and F). Nucleomegaly
was observed in all cases but preserved N:C ratio lower than
0.5 was present in 14 cases (56%), and increased N:C ratio
(.0.5) was seen in 11 cases (44%) (Figure 1, D). None of the
cases had N:C ratio greater than 0.7. Following the TPS

DISCUSSION
PCUH is a urothelial proliferation with a pseudoinfiltrative growth pattern that can mimic invasive urothelial
carcinoma.1–3,7 However, the lesion appears to be reactive,
and in a large series with extensive follow-up, we
demonstrated that it lacks the association with an increased
subsequent risk of urothelial carcinoma. It has most
commonly been described in the setting of prior radiation.1,2,4 Other known predisposing risk factors include
vascular insufficiency, such as peripheral vascular disease,
chemotherapy, chronic catheterization, or prior prostatectomy.3,4 For a small number of cases, no cause could be
identified. Although the tissue findings of PCUH have been
well described, the urine cytology features of this lesion
have not been studied previously.
Published in 2016,6 TPS introduced a standardized
reporting system that defined specific diagnostic categories
and corresponding required cytomorphologic criteria. A
significant goal of TPS is to detect HGUC while minimizing
the reporting rate of the AUC category, reserving the
category of atypical for features that specifically raise
concern for HGUC.8 Based on TPS diagnostic criteria, most
urine specimens in which morphologic alterations of
urothelial cells can be attributed to a known etiology (eg,
therapy effect, stones, infectious processes) should be
excluded from the AUC category and classified as NHGUC.9
A recently published second edition of TPS10 explains how
certain morphologic features, such as cellular degeneration,
poor preparations, reparative changes, and other artifacts,
can increase diagnostic uncertainty, making the interpretation of benign versus malignant more difficult. The concept
of AUCs can be better explained when seeing it as a
probability. It represents the potential of atypical cytologic
features being more than just benign/reactive changes and
indicates that the cytomorphologic findings are abnormal
and suggest the presence of worrisome cells.10,11 TPS criteria
for AUCs, suspicious for high-grade urothelial carcinoma
(SHGUC), and HGUC categories were set by using the
following morphologic features: (1) increased N:C ratio
(.0.5 or .0.7), (2) nuclear hyperchromasia, (3) nuclear
membrane irregularity, and (4) chromatin pattern. The
major criterion for AUCs is the presence of urothelial cells
with N:C ratio greater than 0.5, and the minor criteria, of
which only one is required, include (1) mild nuclear
hyperchromasia, (2) irregular nuclear membranes, and (3)
irregular, coarse, clumped chromatin. The major criteria for
SHGUC are urothelial cells with an N:C ratio greater than
0.7 and severe nuclear hyperchromasia. The minor criteria,
of which only one is required, include (1) irregular nuclear
membranes and (2) very dark, irregular, coarse, clumped
chromatin. SHGUC is confirmed when a limited number of
diagnostic cells are present. For the diagnosis of HGUC, 10
or more cells qualifying for SHGUC should be present.6
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Figure 1. A, Low-power magnification of pseudocarcinomatous urothelial hyperplasia (PCUH) showing prominent dilated blood vessels with fibrin
thrombi, blood extravasation, and inverted urothelial proliferation. B, Higher magnification of PCUH showing extensive inverted proliferation among dilated
blood vessels with fibrin thrombi. C, Earlier changes of PCUH with only superficial invagination of urothelium. However, extensive blood extravasation,
dilated blood vessels, and scant fibrin thrombi are typical of PCUH. D, The epithelium in PCUH mostly has open chromatin, occasional cells demonstrate
prominent nucleoli, and some cells have prominent cytoplasmic vacuoles. E, Sheet of cells with dense to vacuolated cytoplasm, finely granular to coarse
chromatin, and prominent nucleoli. Most cells have a preserved nuclear-cytoplasmic (N:C) ratio; however, scattered cells have N:C ratios greater than 0.5
(cytospin). F, Cohesive cluster of cells with dense cytoplasm, vesicular nuclei, and prominent nucleoli. The N:C ratio is preserved. Red blood cells are present
(cytospin) (hematoxylin-eosin, original magnifications 34 [A], 320 [B and C], and 340 [D]; Papanicolaou stain, original magnifications 340 [E] and 3100 [F]).
Arch Pathol Lab Med
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Cytologic Features of Pseudocarcinomatous Urothelial Hyperplasia in Urine Cytology Specimens
Case
No.

Original
Diagnosis

N:C
Ratio

Mild Nuclear
Hyperchromasia

Irregular
Nuclear
Membrane

Coarse
Chromatin

Diagnosis
Based on
TPS Criteria

Prominent
Nucleoli

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

NHGUC
NHGUC
NHGUC
NHGUC
AUCs
AUCs
NHGUC
AUCs
AUCs
NHGUC
NHGUC
AUCs
HGUC
AUCs
AUCs

.0.5
,0.5
.0.5
.0.5
.0.5
,0.5
.0.5
,0.5
.0.5
,0.5
,0.5
.0.5
.0.5
,0.5
.0.5

Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
No
No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

AUCs
NHGUC
NHGUC
AUCs
AUCs
NHGUC
AUCs
NHGUC
AUCs
NHGUC
NHGUC
AUCs
AUCs
NHGUC
NHGUC

Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

16

AUCs

,0.5

No

No

No

NHGUC

Yes

17
18
19
20
21
22
23
24
25

NHGUC
NHGUC
NHGUC
AUCs
NHGUC
NHGUC
NHGUC
AUCs
NHGUC

,0.5
.0.5
.0.5
,0.5
,0.5
,0.5
,0.5
,0.5
,0.5

No
No
No
Yes
No
No
No
No
No

No
Yes
Yes
Yes
No
Yes
No
Yes
No

No
No
No
No
No
No
No
No
No

NHGUC
AUCs
AUCs
NHGUC
NHGUC
NHGUC
NHGUC
NHGUC
NHGUC

Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes

Cytoplasm
Dense to finely vacuolated
Vacuolated
Dense
Vacuolated
Dense to finely vacuolated
Dense
Dense to finely vacuolated
Dense to finely vacuolated
Dense to finely vacuolated
Dense
Dense to finely vacuolated
Dense and vacuolated
Finely vacuolated
Dense to finely vacuolated
Dense, finely vacuolated, and
vacuolated
Dense, finely vacuolated, and
vacuolated
Finely vacuolated and vacuolated
Finely vacuolated and vacuolated
Finely vacuolated
Dense
Dense to finely vacuolated
Dense to finely vacuolated
Dense and vacuolated
Finely vacuolated
Finely vacuolated

Abbreviations: AUCs, atypical urothelial cells; HGUC, high-grade urothelial carcinoma; N:C, nuclear-cytoplasmic; NHGUC, negative for highgrade urothelial carcinoma; TPS, The Paris System for Reporting Urinary Cytology.

The key cytomorphologic features observed in PCUH
include sheets, clusters, or isolated urothelial cells with
dense squamoid to vacuolated cytoplasm, nucleomegaly
with preserved N:C ratio, vesicular to finely granular
chromatin with prominent nucleoli, smooth to mildly
irregular nuclear membrane, and nuclear grooves. However,
in a significant proportion of cases, the cells exhibited mild
nuclear hyperchromasia, irregular nuclear membrane, and
increased N:C ratio (.0.5), or variable combinations
thereof, which possibly triggered an original diagnosis of
AUCs and HGUC. As the cytomorphologic features of
PCUH have not been previously defined in the setting of
TPS, and not all features may be present in every specimen,
this entity can pose a diagnostic challenge. The presence of
dense squamoid to vacuolated cytoplasm, vesicular nuclei
with prominent nucleoli, and preserved N:C ratio should be
recognized as a reactive change, since these features are rare
in HGUC.9,12,13
The typical background features of PCUH in tissue
specimens include inflammation, vascular congestion, blood
extravasation, and fibrin clots.1–4 We specifically assessed
the background findings in our cytology specimens with
features of PCUH to determine its composition. Most cases
had acute inflammation and/or red blood cells. Necrotic
debris or tumor diathesis was not present. These findings
were observed in both cytospin and ThinPrep preparations.
In most cases, PCUH developed in patients with prior
malignancy and radiation therapy to the pelvic region,

particularly prostate cancer. Other malignancies of the
urinary tract or metastases are rare and may have distinct
cytologic features, but many secondary tumors, particularly
adenocarcinomas, may occasionally shed tumor cells into
the urine and create diagnostic difficulties.14–17 Most
secondary neoplasms represent direct invasion by tumors
originating in adjacent sites (most commonly the female
genital tract, prostate, and lower gastrointestinal tract) and a
minority of tumors represent metastases (most commonly
from skin, stomach, breast, and lung).16,18 Primary bladder
adenocarcinomas have cytologic features overlapping with
those of colorectal primary.16,17 In PCUH, the presence of
tight, cohesive clusters of atypical cells with enlarged nuclei,
prominent nucleoli, vesicular to finely granular chromatin,
and increased N:C ratio can mimic adenocarcinoma. This
may also present a potential diagnostic pitfall for patients
with recent radiation therapy for prostate cancer, given that
reactive changes seen in PCUH can have morphologic
overlap with prostate cancer cytology. However, in cases
with a long interval between radiation and PCUH diagnosis,
the history of previous radiation may be unknown or
deemed unimportant by the patient or a referring provider.
Prostatic adenocarcinoma is usually composed of acinar
structures with round nuclei, vesicular chromatin, and
prominent nucleoli; additionally, the tumor cells are positive
for NKX3.1 and prostate-specific antigen by immunohistochemistry.15,17 For adenocarcinomas of gynecologic origin,
PAX8, estrogen receptor, progesterone receptor, and p16
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Figure 2. A, Cohesive group of cells with glassy nuclei, smooth nuclear membrane, and finely vacuolated to vacuolated cytoplasm (cytospin). B,
Sheet of cells with enlarged, vesicular nuclei, prominent nucleoli, and nuclear grooves. Inflammation and red blood cells are present (cytospin). C,
Cluster of atypical cells with enlarged nuclei, mild hyperchromasia, and finely vacuolated cytoplasm (ThinPrep). D, Sheet of cells with dense to
vacuolated cytoplasm, finely granular chromatin, smooth to mildly irregular nuclear membrane, and prominent nucleoli (cytospin). E, Group of cells
with mild nuclear enlargement, mild nuclear membrane irregularity, granular chromatin, and abundant intracytoplasmic vacuolization (cytospin). F,
Isolated cells with mild nuclear enlargement, granular chromatin, mild nuclear membrane irregularity, nuclear grooves, prominent nucleoli, and
cytoplasmic vacuolization. The vacuolated cytoplasm, along with the prominent nucleoli, should point toward a reactive process (cytospin)
(Papanicolaou stain, original magnifications 340 [B], 360 [D], and 3100 [A, C, E, and F]).
Arch Pathol Lab Med
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immunohistochemistry in conjunction with high-risk human papillomavirus by chromogenic in situ hybridization
can be helpful in determining the site of origin and
differentiating between endocervical and endometrial primary.15 The cytologic diagnosis of primary bladder adenocarcinoma can be more challenging, given that
cytomorphology is not specific, especially in the absence
of clinical history.17 Clinical and radiographic correlations
are highly recommended for confirmation of the diagnosis.
In most cases, urine PCUH cytologic features do not strictly
meet TPS criteria for HGUC, but some cases do meet AUC
criteria. It is also worth noting that AUC criteria specifically
include assessment for the presence of clinical factors
known to cause reactive atypia in urine specimens, such
that the quality of diagnostic interpretation is, in part,
related to the availability of relevant clinical information.
The cytologic features of PCUH can also overlap with those
of other benign urothelial lesions such as cystitis cystica et
glandularis with or without intestinal metaplasia and
nephrogenic adenoma. The presence of cohesive epithelial
groups with cytoplasmic vacuolization in PCUH could be
misinterpreted as glandular-type epithelium such as the one
seen in cystitis cystica et glandularis. However, the glandular
epithelial groups of cystitis cystica et glandularis usually
maintain a columnar architecture, closely resembling endocervical cells, and the cells of PCUH typically have a dense
squamoid cytoplasm. Although cystitis cystic et glandularis
with intestinal metaplasia is considered a benign metaplastic
process, patients with extensive intestinal metaplasia may
have an increased risk of developing bladder adenocarcinoma.19 Thus, these findings should be reported under the
NHGUC category with a note explaining such changes. Like
PCUH, nephrogenic adenoma can show 3-dimensional
cohesive clusters of polygonal cells with slightly increased
N:C ratio, prominent nucleoli, and cytoplasmic vacuolization.20 Distinguishing between these entities may not be
entirely possible on cytomorphologic findings alone. Cell
block may be prepared for immunohistochemistry with
nephrogenic adenoma typically being positive for PAX8 and
negative for GATA3—an immunoprofile opposing that of
urothelial cells seen in PCUH. However, regardless of the
origin of these cells, it is essential to recognize that these
cytologic changes are benign and should be classified as
NHGUC. Occasionally, benign bladder lesions can coexist
with cancer.21 Thus, the presence of benign urothelial
lesion(s) should not prevent one from further assessing for
the presence of neoplasia in urine specimens.
Our multi-institutional series highlights several key
cytomorphologic features of PCUH. Being aware of the
spectrum of cytomorphologic features of PCUH is essential
for providing the most inclusive differential diagnosis and
adequate classification of specimens according to TPS. The
strengths of this study include cytology-histology correlation, large cohort size, and a central review of all cases by a
board-certified cytopathologist, which helped refine and
establish the cytologic features of PCUH. The tentative
limitations are the retrospective design of the study and a
nonblinded review.

nonurothelial malignant neoplasms, creating a potential
diagnostic challenge. In fact, in our cohort, 44% (11 of 25)
of urine cytology specimens with PCUH findings were
initially misclassified as AUCs or HGUC. In a significant
proportion of cases, the presence of nucleomegaly, nuclear
hyperchromasia, nuclear membrane irregularity, and increased N:C ratio (.0.5) may prompt an interpretation of
AUCs. However, in most cases, PCUH does not meet strict
TPS criteria for AUCs or HGUC, and the cytologic changes
should be interpreted as NHGUC. One may consider
providing a more detailed diagnosis by adding a statement
that the cytologic findings are those of PCUH. Unfortunately,
as there are no ancillary studies that can help distinguish
between PCUH and AUCs or HGUC, one must rely on the
overall cytomorphology of PCUH. Recognition of this entity
by cytopathologists when interpreting urine cytology findings
should trigger a review of the patient’s clinical history, as
identification of a predisposing factor(s), particularly prior
radiation therapy, can be revealing and help avoid overinterpreting reactive changes in PCUH cases.
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